A Phase 3 interventional study of IBI306 450mg SC Q4W and Placebo SC Q4W in Hypercholesterolemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-11.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.
Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 11th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2020, is one of 25 in phase 3, and was the 25th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18–85
Novartis Pharmaceuticals · Sites in China, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 20 more countries
Ages 6–11
Hasten Biopharmaceutical Co., Ltd. · Sites in China
Ages 18+
Stephen Nicholls · Sites in China, Australia, India and 6 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 8 · Phase 3 27 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 804 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 207 across the 53 interventional studies, 924 across the 6 observational. Of the 39 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 4 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypercholesterolemia with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07930507Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients | 2027-10-11 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Hypercholesterolemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol(LDL-C) uptake. This study is being done to investigate the effects of IBI306 in Chinese people with non-familial hypercholesterolemia with very high or high cardiovascular risk. This study will see if IBI306 will reduce low density lipoprotein cholesterol (LDL-C) in Chinese people who are taking a certain type of lipid-lowering medication (statins with or without ezetimibe) and whether it causes any side effects
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled study of IBI306 in Chinese non-familial hypercholesterolemia Subjects with very high or high cardiovascular risk. A total of around 600 subjects who meet admission criteria will be randomized and receive one of the two dose levels of IBI306 or matching placebo: 450mg Q4W, or 600mg Q6W. The double blind period for both groups will be 48 weeks. The study will last 52 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Drug: IBI306 450mg SC Q4W
Drug: Placebo SC Q4W
Drug: IBI306 600mg SC Q6W
Other: Placebo SC Q6W
Subjects will receive IBI306 450mg every 4 weeks subcutaneously.
Subjects will receive placebo every 4 weeks subcutaneously.
Subjects will receive IBI306 600mg every 6 weeks subcutaneously.
Subjects will receive placebo every 6 weeks subcutaneously.
Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 48
Time frame: Week 48
The percent of subjects with LDL-C reduction no less than 50% from baseline
Time frame: Week 48
The percent of subjects with LDL-C<70mg/dL(1.8 mmol/L)
Time frame: Week 48
The percent change in Lp(a),ApoB, non-HDL-c, ApoB/ApoA1 from baseline
Time frame: Week 48
Ran from Apr 2020 to primary completion in Feb 2022, 21 months.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafolecimab
Innovent Biologics (Suzhou) Co. Ltd. →